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INTRODUCTION
Endometriosis is a gynecologic disease that stems
from the presence of uterine endometrial tissue
(both glands and stroma) outside the uterine
cavity.1 These ectopic tissues are often planted on
the pelvic viscera, e.g. ovaries, and the peritoneum.
It is a disease of primarily women of reproductive
age. While studies vary on its prevalence in the
general population, it is estimated that endome-
triosis adversely affects 1 in every 10 women.2
Endometriosis acquaints itself with numerous risk
factors, e.g. infertility, early age at menarche,
shorter menstrual cycle length, history of endo-
metriosis in 1st degree relative and diet high in fat
and alcohol.1 Nevertheless, there are numerous
protective factors against endometriosis, e.g. use of
oral contraceptive drugs, increased BMI, exercise
and diet high in vegetables and fruits.1,2
Abstract
Objective: To investigate the reproductive benefits of combining
laparoscopic surgery with GnRH-agonist hormonal therapy in
treating women with endometriosis.
Methods: This is a non-randomized prospective analytic study of
patients with endometriosis conducted in a private hospital in
Bandung during the period of January 2014 to December 2015,
whom were later followed up after 12-24 months for assessment
of post-surgical reproductive performance. A total of 121 patients
were enrolled, 60 of which received post-surgical GnRH-agonist
hormonal therapy.
Results: We discovered that 56 women (46.3%) eventually
achieved spontaneous conception after surgery but upon further
analysis, it was discovered that GnRH-agonist played no significantly
meaningful role in improving the spontaneous pregnancy rates of
these patients (OR 1.539; 95% CI 0.750-3.159; p-value 0.239).
Furthermore, even though there was a wide range as to when they
achieved conception, those untreated with hormonal therapy
tended to conceive far more quickly than those who were (5.91 
6.28; 8.56  4.24; p-value: 0.011).
Conclusion: Post-laparoscopic GnRH-agonist administration to
women with endometriosis does not significantly improve their
chances of spontaneous conception. In fact, such administration
seems to delay it.
[Indones J Obstet Gynecol 2017; 5-2: 87-93]
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Abstrak
Tujuan: Untuk menyelidiki efek reproduktif dari terapi kombi-
nasi operasi laparoskopi dan terapi hormonal GnRh-agonis
dalam manajemen perempuan dengan endometriosis.
Metode: Penelitian ini adalah studi analitik prospektif tidak teracak
pada pasien-pasien dari sebuah rumah sakit swasta di Bandung dari
tahun 2014-2015 yang menderita endometriosis dan kemudian diikuti
hingga 12-24 bulan untuk mengevaluasi performa reproduktif post-
operatif mereka. Terdapat 121 pasien pada penelitian ini, 60 di anta-
ranya mendapatkan terapi hormonal GnRH-agonis post-operatif.
Hasil: Penelitian ini menemukan bahwa 56 pasien (46,3%) berhasil
hamil setelah dilakukan laparoskopi tetapi disimpulkan bahwa
GnRh-agonis tidak memainkan peranan signifikan dalam mening-
katkan angka kehamilan dari pasien-pasien ini (OR 1,539; 95% CI
0,750-3,159; p 0,239). Selain itu, meskipun terdapat variasi cukup
luas terkait kapan pasien-pasien ini berhasil hamil, mereka yang
tidak mendapatkan GnRH-agonis cenderung berhasil hamil lebih
cepat dibandingkan mereka yang dapat (5,91  6,28; 8,56  4,24;
p 0,011).
Kesimpulan: Pemberian GnRH-agonis post-laparoskopi pada pasien-
pasien dengan endometriosis tidak meningkatkan kemungkinan
mereka hamil dan sebaliknya, cenderung menunda kehamilan.
[Maj Obstet Ginekol Indones 2017; 5-2: 87-93]
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Despite being a common gynecologic disease,
the exact cause of endometriosis remains elusive
and the available theories seem to offer only part
of the explanation. The most widely supported
theory is the transplantation theory proposed by
Sampson which assumed that retrograde mens-
truation into the peritoneal cavity allowed the
implantation of sloughed endometrial tissue on the
pelvic viscera and/or peritoneum.1,2 This, together
with heightened inflammatory state, reduced
apoptosis and evasion from NK cells predation,
have allowed the endometrial tissue to not just
implant but also persist and flourish in their
foreign territories.2,3 There are other theories,
including the coelomic metaplasia and the
induction theories, which attempt to explain the
histogenesis of endometriosis and it seems more
likely that an eclectic mix of the various theories
available today underlies the true pathomechanism
of endometriosis.1
To date, endometriosis has many classification
systems, but the original one, proposed for the
ASRM remains the benchmark today. This classifi-
cation divides endometriosis into 4 groups, ranging
from stage I (minimal endometriosis) to stage IV
(severe endometriosis). There are other systems,
such as the Endometriosis Fertility Index (EFI)
primarily used to predict pregnancy rates of
patients based on their endometriosis severity,
and the Enzian classification for classifying deep
infiltrative endometriosis.4
Endometriosis adversely affects the quality of
life of many females as it primarily produces pain.
Various types of pain have been reported, including
dysmenorrhea, dyspareunia, dyschesia and non-
menstrual pelvic pain.5 Even more unfortunate has
been the revelation that the painful symptoms are
only part of the misfortune befalling these patients
as endometriosis is also linked to infertility.6,7
There are several causes of infertility, conven-
iently divided into 3 groups: ovulatory dysfunction
(20-40%), tubal and peritoneal pathology (30-
40%) and male factors (30-40%).8 Endometriosis
causes ovulatory dysfunction, induces a heightened
inflammatory state in the peritoneum and
fertilization-hampering changes in peritoneal fluid
while also disrupting the hormonal interaction in
the uterus.7
Fortunately, the ESHRE has published a guide-
line for the management of endometriosis, in the
hope of providing relief and also restoring the
reproductive function of the patients.9,10 The
ESHRE recommends laparoscopic surgery as a
means to remove the endometriosis lesions
and also reduce endometriosis-associated pain.9
Another justification for surgery comes from the
observation that endometriosis appears to
progress in 30-60% of patients within a year of
diagnosis and it is not possible to predict which
patients’ endometriosis will worsen. Fortunately,
surgery is deemed to live up to its hype as spon-
taneous conception is to be expected within the 1st
year post-surgery.11
There is also a widespread practice today of
adding adjuvant medical therapy in the form of
GnRH-agonist injections after laparoscopic surgery
for these patients. This hormonal therapy should
reduce and/or postpone endometriosis recurrence
by inactivating, but not eliminating, the remaining
microscopic endometriosis lesions.12,13 Current
evidence states that this regimen is more effective
than surgery alone in reducing the symptoms and
recurrence of endometriosis but its effects
on increasing pregnancy rate are still up to
debate.14,15
Therefore, this study aims to evaluate the repro-
ductive performance of patients with endome-
triosis who underwent operative laparoscopy 12-
24 months post-surgery and also the association,
if any, between post-surgical GnRH agonist
administration and pregnancy rates. To our
knowledge, this is the first study in Indonesia
that attempts this approach on endometriosis
patients.
METHOD
This is a non-randomized prospective analytic
study involving a cohort of patients in a private
hospital in Bandung who was operated by a single
physician between January 2014 and December
2015 for various complaints, e.g. dysmenorrhea
and inability to conceive and subsequently
discovered to harbor endometriosis as one of the
post-surgical diagnoses. Surgical treatment was
performed in a standardized manner following
hospital protocols. Laparoscopy was performed
under general anesthesia using a 4-port approach.
When an ovarian endometrioma(s) was dis-
covered, ovarian cystectomy began with adhe-
siolysis. Once the ovary was mobilized, the ovarian
cortex was grasped with forceps and incision of
the cortex was made. If the cyst was opened and
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there was a spillage, peritoneal irrigation as
performed. Upon cyst decompression, its wall was
exposed, inspected and finally stripped from the
normal ovarian tissue. Should there be any
bleeding from the cortex after stripping, such
bleeding zones were coagulated using the bipolar
forces. The endometrioma was then removed
through a 10-mm trocar. When a peritoneal
endometriosis was encountered, endometriosis
removal was done through ablation. Adhesiolysis
was first performed to obtain proper visualization
of the lesions. The lesions were then destroyed
using either bipolar coagulation or laser vaporiza-
tion. Vaporization was continued until no pigment
remained to be seen.16 Documentation of endo-
metriosis location and rASRM stage was under-
taken. All the surgeries were undertaken by a
single physician (T.D) to minimize operator bias.
Routine follow-up consisted of an obligatory post-
operative visit at 1-2 weeks where a physical
examination was done and patients were ques-
tioned regarding their bowel and bladder func-
tions. Planning on whether to treat the patient with
an adjuvant hormonal therapy (i.e., GnRH-agonist
injections) was made during this consultation and
should a patient be recommended to undergo such
therapy, a repeat consultation was arranged at 2-4
weeks during which she would receive her first
GnRH-agonist injection. Patients would normally
receive either 3 or 4 monthly injections, and the
decision to assign which regimen to which patients
was subject to the physician’s (T.D) clinical assess-
ment.
Women identified as having endometriosis of
any rASRM stage were then contacted by telephone
from November to December 2016 (on at least 2
separate days for those who didn’t respond to our
first call) and were requested, by phone, for their
consent to participate in the study and divulge
their post-surgical reproductive performance. The
following items were collected during the inter-
views: any pregnancy and/or abortion post-
surgery; any additional GnRH-agonist injection(s)
post-surgery for those whose records were in-
complete and/or who had to receive their monthly
injections elsewhere due to various reasons; and
details of the pregnancy and its outcome for those
who did conceive which included the last mens-
trual date, mechanism of pregnancy (spontaneous
conception, intrauterine insemination (IUI), IVF/
ICSI)), gender of the child, weight and length of
the child at delivery, date of delivery, means of
delivery and site of delivery.
Initially, 166 eligible patients were identified
from our 2014-2015 databases to participate in
this study. However, 45 patients had to be opted
out due to one or more of the following reasons:
the patient did not respond to telephone calls on
2 separate days; the patient’s contact numbers
were inactive, out of reach or incorrect; the patient
already had children prior to surgery and did not
desire to conceive again; the patient was already >
42 years old at the time of surgery; the patient was
widowed prior to surgery and did not remarry; the
patient was unmarried until the time of follow-up
and the patient’s successful conception was by
assisted reproduction technology (ART). In the
end, 121 patients were included in the final cohort
for analysis.
Data were then recorded in a purpose-built
database on Microsoft Excel with subsequent
statistical analysis undertaken with Statistical
Package for Social Sciences (SPSS), version 21. An
80% power was assigned at the beginning of the
study, which determined the sample size for each
group. Shapiro-Wilk’s test was then used to
determine the data’s normality. Chi-squared and
Mann-Whitney U tests were later used to analyze
the data. Finally, probability values of less than 5%
were considered statistically significant.
RESULTS
Table 1. Demographics of Study Population
Variables GnRH­agonist (+) GnRH­agonist (­) p­value (Sig.)
Age during surgery (mean SD) 29.88  3.87 31.62  3.93 0.014
Pre-surgical reproductive history
Parturition
0 52 56
 1 8 5
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From January 2014 to December 2015, 166
patients underwent fertility-preserving operative
laparoscopy by a single surgeon for varying states
of endometriosis (stages I-IV) at a private hospital
in Bandung, Indonesia. Follow-up was performed
over the course of 2 months, from November
to December 2016. Data were retrieved from
121/166 patients (72.9%), whom were then
divided into two groups: those who received
GnRH-agonist injections after surgery and those
who didn’t. On average, those who received GnRH-
agonist injections were younger at the time of
Variables GnRH­agonist (+) GnRH­agonist (­) p­value (Sig.)
Abortion
0 52 56
 1 8 5
GnRH-ag inj.
 3 27 N/A
 4 34 N/A
Post-surgical reproductive history
ongoing pregnancy 12 5
parturition 15 16
abortion 4 4
Timing of pregnancy post-surgery* (mean  SD) 8.56  4.24 5.91  6.28 0.011
range of timing (3-21) (0-26)
Pregnancy outcome (parturition) 15 16
Gender
Male 7 13
Female 8 3
Average weight (g) 3008.67  326.49 2980  397.06 0.770
Average length (cm) 49.13  1.25 48.38  1.79 0.232
Status at delivery
preterm 4 5
term 9 10
postterm 2 1
Weight status at delivery
SGA 1 2
AGA 14 14
LGA 0 0
*some patients’ details who had abortion were missing, so calculation of the average timing could not include all 56 patients
Table 2. Spontaneous Conception Rates among Study Population
Pregnant (+) Pregnant (­) Total
GnRH-agonist (+) 31 29 60
GnRH-agonist (-) 25 36 61
Total 56 65 121
Odd-ratio: 1.539 (95% CI 0.750 - 3.159), p-value: 0.239
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surgery than those who didn’t (p-value 0.014).
Then, for both groups, most women had never
conceived prior to surgery (108/121 patients,
89.3%). Among those who received GnRH-agonist
injections, the number of women who received 3
monthly injections or less (27 patients) was
slightly lower than those who received 4 monthly
injections or more.
After surgery, the reproductive performances of
the two groups were compared. Firstly, of those
whom are currently pregnant, two-thirds come
from those who received GnRH-agonist injections
post-surgery (12 to 5, respectively). Secondly,
about the same number of patients from both
groups have delivered a child after undergoing
laparoscopic surgery (15 and 16, respectively).
Finally, the same number of patients from both
groups have experienced an abortion after the
surgery (4 and 4, respectively).
Thus, in total 56 patients managed to sponta-
neously conceive after surgery. However, when the
association between the administration of GnRH-
agonist (regardless of the number of injections
received by the patients) and spontaneous preg-
nancy rates was investigated, the Chi-squared test
revealed no significant role to be played by GnRH-
agonist injections in increasing spontaneous preg-
nancy rate (OR 1.539; 95% CI 0.750-3.159; p-value
0.239).
Of those who did conceive though, there was a
wide range as to when they managed to conceive.
Some conceived immediately after surgery (a
patient managed to conceive within a single month
after surgery) while others had to wait significantly
longer to achieve pregnancy (the longest was 26
months). On average, though, those who did not
receive GnRH-agonist injections tended to conceive
significantly more quickly than those who did
(5.91  6.28; 8.56  4.24; p-value: 0.011).
Of those who delivered, both groups yielded
notable results. Firstly, those who received
GnRH-agonist injections had more female children
while those who did not, delivered pre-
dominantly male children. Secondly, there were
no significant differences on the average weights
and lengths of the children at delivery across the
two groups (p-value 0.770 and 0.2332, respec-
tively). Finally, most of the deliveries were at term
(19/31; 61.3%) and had normal weights at
delivery (28/31; 90.3%)
DISCUSSION
Endometriosis is a benign gynecologic disease
defined by the ectopic presence of endometrial
tissue outside the uterus.8 It affects the pelvic
viscera and/or peritoneum and characteristically,
it is often present in the most declivitous parts of
the pelvis, such as the Douglas pouch. Its charac-
teristic symptom is pain, manifesting as dysmenor-
rhea, dyspareunia, dyschesia and non-menstrual
pelvic pain.5 The symptoms may be so severe that
it degrades the patient’s quality of life (QoL) as well
as debilitating the patient from performing her
daily activities. It is this painful characteristic of
endometriosis that has prompted ESHRE to
recommend laparoscopic surgery as a means to
both diagnose and treat endometriosis.9 ESHRE
recommends operative laparoscopy to both relieve
the patient of endometriosis-associated pain as
well as preserve the patient’s fertility. An
Australian study by Abbott et al lent support to this
ESHRE recommendation as patients who
underwent surgery for endometriosis reported
significant improvement for the above-mentioned
4 pain symptoms, the patient’s QoL and sexual
pleasure. Relieved of endometriosis, the patients
later should try to conceive naturally for at least
12 months prior to resorting to assisted repro-
ductive technology (ART). This is a recommen-
dation of at least 2 studies from France and
Australia.5,11
In the present study, 56 out of 121 patients
(46.3%) managed to conceive naturally. This is a
comparable rate of conception when compared to
a study in Australia in which they analyzed the
spontaneous conception rate among nurses who
underwent laparoscopic surgery for endometriosis
and got a spontaneous conception rate of 46.5%
(66/142 patients).10 In addition, our results are
slightly more superior to another similar study in
Korea, in which they analyzed the natural concep-
tion rate among women who had their endome-
triosis surgically removed.17 The Korean study
exhibited a 41.4% conception rate but a major
difference was their follow-up period, which was
limited to only 12 months post-laparoscopy. Had
they extended the follow-up period to match ours
(12-24 months post-laparoscopy), it would be
realistic to assume their natural conception rate
would have been higher.
In our present study, our patients were divided
into two equally sized groups: those who received
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GnRh-agonist monthly injections post-surgery and
those who didn’t. The GnRH-agonist used in this
study was leuprolide, falling under two brand
names: Tapros and Divalin . Of those who received
the injections, slightly more patients (34 patients)
received at least 4 injections than those who
received only 3 injections or less (27 patients).
When this exposure was accounted for and
compared towards the natural conception rates of
each group’s members, it was revealed that the
administration of a GnRH-agonist did not signifi-
cantly improve natural conception rates. This is in
agreement with many other studies that have
also been conducted throughout the years.14,18-21
A study in Germany by Alkatout et al even went a
step further, by analyzing conception rates from
women with endometriosis treated with hormonal
therapy alone, surgical therapy alone, and
combined surgical-hormonal therapy. The results
they had led to the same conclusion, that there
were not any significant differences in the natural
conception rates across the 3 different groups.14 In
fact, this result is to be expected, as the primary
rationale to prescribe GnRH-agonist injections
after laparoscopic surgery is to prevent endome-
triosis recurrence by inactivating any remaining
microscopic endometriosis lesions and not to
directly improve fertility.22,23 The mechanism by
which GnRh-agonist administration prevent
sendometriosisre currence is by abolishing the
pulsatile release of follicle-stimulating hormone
(FSH) and luteinizing hormone (LH), thereby
inactivating the ectopic endometrial lesions which
would otherwise grow along the pulsatile FSH and
LH secretion.24 However, it is important to stress
that such hormonal therapy only function to
inactivate and not eliminate the ectopic endo-
metrial lesions. GnRH-agonist and all forms of
hormonal therapy place the ectopic endometrial
tissue in a quiescent state and as long as the drug
is administered, the patient may expect to remain
free of endometriosis symptoms.13
It is interesting to note that upon further
analysis, there is a significant difference in the
average waiting time to pregnancy after surgery
between those who were treated with GnRH-
agonist and those who were not. In our results,
those who did not receive GnRH-agonist
injections had to wait significantly less to conceive
(5.91  6.28) than those who did (8.56  4.24),
p-value: 0.011. This result does support the views
expressed in other studies, which recommended
patients to attempt natural conception for at least
12 months post-surgery before requesting the help
of ART.10,11
However, as with all other scientific studies, our
study is still replete with limitations from various
aspects. The first is selection bias, introduced by
the non-randomized nature of this study and also
the specific population from which the study
participants were recruited, as they all came from
a single private hospital. The second limitation was
the relatively small cohort of patients this study
could work with (only from 2014-2015) and this
small pool was further hampered by non-
responders, which would have introduced non
response bias. Another limitation was with the
presence of possible confounders, e.g. male factor
infertility and the presence of other gynecologic
comorbidities. Finally, missing details from the
medical records also disallowed us from stratifying
the endometriosis diagnosis into the rASRM
classification.
CONCLUSION
To conclude, post-laparoscopic administration of
GnRH-agonist to women with endometriosis does
not significantly improve their spontaneous
conception rates. In fact, those who had post-
laparoscopic GnRH-agonist injections tended to
wait longer before eventually conceiving.
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